Pembrolizumab

Research use only, not for human use.

Pertuzumab anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.

Pertuzumab anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.

Pembrolizumab (MK-3475) increases the secretion of cytokines IFN-γ, TNF-α and the apoptotic cell death of A549 cells. Pembrolizumab improves the αROR1-CAR T-mediated cytotoxicity, and reduces tumorigenesis in the co-cultured αROR1-CAR T and A549 cells by blocking PD-1::PD-L1 interaction in αROR1-CAR T cells. Cell Cytotoxicity Assay Cell Line:αROR1-CAR T and A549 cells Concentration:10 μg/mL Incubation Time:Adding Pembrolizumab after A549-Red-Fluc cells preconditioned in elevated pressure (+ 100 mmHg) for 7 days.Result:Enhanced αROR1?CAR T killing of A549 lung cancer cells under elevated pressure.Apoptosis AnalysisCell Line:A549 cells Concentration:10 μg/mL Incubation Time:Result:Increased the apoptotic cell death in A549 cells, and improve the αROR1-CAR T-mediated cytotoxicity.

Pembrolizumab inhibits tumor size in A549 xenograft mice pretreated by pressure. Animal Model:Six-week-old male BALB/c athymic nude mice Dosage:5 mg/kg Administration:Pembrolizumab (5 mg/kg; Intravenous injection; Once)Result:Reduced tumorigenesis in αROR1-CAR T cells and co-cultured with A549 cells.

——

Immunology/Inflammation

PD-1/PD-L1

PD-1

——

——

1374853-91-4

149 kDa

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years